Literature DB >> 22709754

Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT).

Xavier Freixa1, Vladimír Džavík, Sandra A Forman, James M Rankin, Christopher E Buller, Warren J Cantor, Witold Ruzyllo, Harmony R Reynolds, Gervasio A Lamas, Judith S Hochman.   

Abstract

BACKGROUND: The OAT, a randomized study of routine percutaneous coronary intervention or optimal medical therapy (MED) alone for the treatment of a totally occluded infarct-related artery in the subacute phase after myocardial infarction, showed similar rates of death, reinfarction and congestive heart failure (CHF) between study groups. Although most percutaneous coronary intervention patients were treated with bare metal stents (BMS), drug-eluting stents (DES) were also implanted in the latter part of the study. The aim of the study was to conduct an exploratory analysis of long-term outcomes for DES vs. BMS deployment vs. MED in the OAT.
METHODS: Patients enrolled after February 2003 (when first DES was implanted) were followed (DES n = 79, BMS n = 393, MED n = 552) up to a maximum of 6 years (mean survivor follow-up 5.1 years).
RESULTS: The 6-year occurrence of the composite end point of death, reinfarction and class IV CHF was similar [20.4% of DES, 18.9% of BMS and 18.4% of MED (P = .66)] as were the rates of the components of the primary end point. During the follow-up period, 33.4% of DES, 44.4% of BMS and 48.1% of MED patients, developed angina (P = .037). The rate of revascularization during follow up was 11.3%, 20.5% and 22.5% among these groups, respectively (P = .045).
CONCLUSIONS: There is no suggestion of reduced long-term risk of death, reinfarction or class IV CHF with DES usage compared to BMS or medical treatment alone. An association between DES use and freedom from angina and revascularization relative to medical therapy is suggested.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22709754      PMCID: PMC3735135          DOI: 10.1016/j.ahj.2012.03.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  20 in total

Review 1.  Importance of collateral circulation in coronary heart disease.

Authors:  Colin Berry; Kanarath P Balachandran; Philippe L L'Allier; Jacques Lespérance; Raoul Bonan; Keith G Oldroyd
Journal:  Eur Heart J       Date:  2007-01-11       Impact factor: 29.983

2.  Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial.

Authors:  Ph Gabriel Steg; Arthur Kerner; G B John Mancini; Harmony R Reynolds; Antonio C Carvalho; Viliam Fridrich; Harvey D White; Sandra A Forman; Gervasio A Lamas; Judith S Hochman; Christopher E Buller
Journal:  Circulation       Date:  2010-06-14       Impact factor: 29.690

3.  Coronary intervention for persistent occlusion after myocardial infarction.

Authors:  Judith S Hochman; Gervasio A Lamas; Christopher E Buller; Vladimir Dzavik; Harmony R Reynolds; Staci J Abramsky; Sandra Forman; Witold Ruzyllo; Aldo P Maggioni; Harvey White; Zygmunt Sadowski; Antonio C Carvalho; Jamie M Rankin; Jean P Renkin; P Gabriel Steg; Alice M Mascette; George Sopko; Matthias E Pfisterer; Jonathan Leor; Viliam Fridrich; Daniel B Mark; Genell L Knatterud
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

4.  3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).

Authors:  Scot Garg; Patrick Serruys; Yoshinobu Onuma; Cécile Dorange; Susan Veldhof; Karine Miquel-Hébert; Krishnankutty Sudhir; Jean Boland; Kurt Huber; Eulogio Garcia; Jan A M te Riele
Journal:  JACC Cardiovasc Interv       Date:  2009-12       Impact factor: 11.195

5.  Appraising the pathophysiologic impact of coronary collaterals as measured by fractional flow reserve on symptoms and signs of myocardial ischemia.

Authors:  Claudio Moretti; Giuseppe Gl Biondi-Zoccai; Filippo Sciuto; Pierluigi Omedè; Maria Teresa Lucciola; Luisa Morena; Walter Grosso Marra; Gian Paolo Trevi; Imad Sheiban
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2008-11       Impact factor: 2.160

6.  Fatality, morbidity and quality of life in patients with refractory angina pectoris.

Authors:  Paulin Andréll; Olof Ekre; Lars Grip; Peter Währborg; Per Albertsson; Tore Eliasson; Anders Jeppsson; Clas Mannheimer
Journal:  Int J Cardiol       Date:  2009-10-31       Impact factor: 4.164

7.  Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study).

Authors:  Braim M Rahel; Gerrit J Laarman; Johannes C Kelder; Juriën M Ten Berg; Maarten J Suttorp
Journal:  Am Heart J       Date:  2008-11-06       Impact factor: 4.749

8.  The impact of angina and cardiac history on health-related quality of life and depression in coronary heart disease patients.

Authors:  Shannon Gravely-Witte; Véronique De Gucht; Willem Heiser; Sherry L Grace; Thérèse Van Elderen
Journal:  Chronic Illn       Date:  2007-03

9.  Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial.

Authors:  Vladimír Dzavík; Christopher E Buller; Gerard Devlin; Ronald G Carere; G B John Mancini; Warren J Cantor; Pawel E Buszman; James M Rankin; Carlos Vozzi; John R Ross; Sandra Forman; Bruce A Barton; A Gervasio A Lamas; Judith S Hochman
Journal:  Catheter Cardiovasc Interv       Date:  2009-05-01       Impact factor: 2.692

10.  Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial.

Authors:  Suzanne V Arnold; David A Morrow; Yang Lei; David J Cohen; Elizabeth M Mahoney; Eugene Braunwald; Paul S Chan
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-06-02
View more
  1 in total

1.  Invasive reperfusion after 12 hours of the symptom onset remains beneficial in patients with ST-segment elevation myocardial infarction: Evidence from a meta-analysis of published data.

Authors:  Hai-Tao Yang; Wen-Juan Xiu; Ying-Ying Zheng; Fen Liu; Ying Gao; Xiang Ma; Yi-Ning Yang; Xiao-Mei Li; Yi-Tong Ma; Xiang Xie
Journal:  Cardiol J       Date:  2018-04-03       Impact factor: 2.737

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.